Collectively, these findings underscore the important role of TUBA1C in inducing ICB resistance and its contribution to disease progression, highlighting its potential as a target to improve ICB responses and prognosis in ccRCC. This evidence concerns the gene TUBA1C and nonpapillary renal cell carcinoma.